-
2022-503090-11-00
4
2024-05-23
Hodgkin lymphoma
-
2023-503219-14-01
10
2024-05-22
systemic sclerosis associated interstitial lung disease
-
2023-506308-24-00
10
2024-05-22
Recurrent or metastatic head and neck squamous cell carcinoma
-
2023-505929-14-00
5
2024-05-21
Systemic Lupus Erythematosus
-
2023-508818-42-00
10
2024-05-21
Generalized Epidermolysis Bullosa Simplex (EBS)
-
2023-503631-18-01
5
2024-05-20
Nervous system diseases
-
2023-507677-18-00
9
2024-05-17
Chronic Myeloid Leukemia
-
2023-504151-27-00
5
2024-05-09
Psychosis associated with Alzheimer’s Disease
-
2023-504600-28-00
10
2024-05-09
Metastatic Hepatocellular Carcinoma (HCC)
-
2024-511397-70-00
4
2024-05-06
metastatic renal cell carcinoma (mRCC)
-
2023-505995-31-00
7
2024-05-03
Glanzmann Thrombasthenia
-
2023-505039-11-00
4
2024-05-02
breast cancer, HER2-positive, oligometastatic disease
-
2023-505602-42-00
4
2024-04-30
Spinal Muscular Atrophy (SMA)
-
2024-516498-57-00
4
2024-04-30
liver predominant intrahepatic cholangiocarcinoma
-
2024-511886-12-00
4
2024-04-29
Unfavorable intermediate/high risk prostate cancer patients
-
2022-502276-23-00
5
2024-04-25
JAK2V617F-positive high-risk Polycythemia Vera
-
2023-505660-11-00
5
2024-04-24
Cholangiocarcinoma (LTT, 26.0)
-
2023-504044-34-00
4
2024-04-17
Untreated Chronic Lymphocytic Leukemia
-
2022-501119-14-01
4
2024-04-16
Ulcerative Colitis
-
2023-504865-21-00
5
2024-04-15
Essential Thrombocythemia patients who have an inadequate response to
-
2023-503317-29-00
5
2024-04-12
Metastatic renal cell carcinoma (mRCC)
-
2023-504374-38-00
5
2024-04-12
Locally advanced cervical cancer
-
2024-516563-86-00
4
2024-04-11
Spinal and Bulbar Muscular Atrophy
-
2024-512829-81-00
4
2024-04-10
Adult patients treated in VA ECMO/Impella for cardiogenic shock/cardia